What does obtaining orphan drug designation in Europe mean and why is it key to innovation in ALS?
Orphan drug designation in Europe is a regulatory recognition granted by the EMA to treatments intended for rare diseases, such as ALS. This status provides key incentives—such as market exclusivity and scientific support—that reduce investment risk and accelerate therapeutic innovation, driving the development of new options for patients with urgent unmet medical needs.